Advertisement

Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials

Published:March 21, 2017DOI:https://doi.org/10.1016/j.clgc.2017.03.004

      Abstract

      Background

      Clinical data from patients with non–clear cell renal cell carcinoma (nccRCC) receiving targeted therapy are limited, and many clinical trials have excluded these patients from study entry. We sought to investigate the outcomes of patients with nccRCC treated in clinical trials in the modern era compared with the outcomes of patients with clear cell RCC (ccRCC).

      Patients and Methods

      We conducted a retrospective study of patients with metastatic RCC who had received targeted therapy in Pfizer-sponsored phase II and III clinical trials from 2003 to 2013. Associations between the histologic type and treatment outcome (overall survival [OS] and progression-free survival [PFS]) were assessed using the log-rank test on univariate analysis or the Wald χ2 test from Cox regression on multivariable analysis, adjusted for baseline characteristics, including age, sex, Eastern Cooperative Oncology Group performance status, body mass index, International Metastatic RCC Database Consortium risk factors, previous nephrectomy, previous therapy, metastatic sites, angiotensin system inhibitor use, and statin use.

      Results

      We identified 4527 patients with metastatic RCC: 4235 with ccRCC and 337 with nccRCC. Overall, the median OS was shorter for those with nccRCC than for those with ccRCC (15.7 vs. 20.2 months; hazard ratio [HR], 1.41; 95% confidence interval 1.22-1.63; P < .001). When stratified by the International Metastatic RCC Database Consortium risk group, the median OS was inferior for the intermediate- and poor-risk patients with nccRCC than for those with ccRCC. However, no differences were found in the favorable risk group for nccRCC versus ccRCC. The patients with nccRCC who had received vascular endothelial growth factor-targeted therapy had shorter PFS compared with that of ccRCC patients (median, 6.1 vs. 8.5 months; HR, 1.49; P < .001) but similar PFS when treated with mammalian target of rapamycin inhibitors (median, 4.3 vs. 4.4 months; HR, 0.92; P = .63).

      Conclusion

      Our findings have confirmed that patients with nccRCC are underrepresented in clinical trials and highlight the need for further prospective studies exploring current and novel agents for this patient population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lopez-Beltran A.
        • Scarpelli M.
        • Montironi R.
        • Kirkali Z.
        2004 WHO classification of the renal tumors of the adults.
        Eur Urol. 2006; 49: 798-805
        • Moch H.
        • Cubilla A.L.
        • Humphrey P.A.
        • Reuter V.E.
        • Ulbright T.M.
        The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours.
        Eur Urol. 2016; 70: 93-105
        • Kroeger N.
        • Xie W.
        • Lee J.L.
        • et al.
        Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
        Cancer. 2013; 119: 2999-3006
        • Hudes G.
        • Carducci M.
        • Tomczak P.
        • et al.
        Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
        N Engl J Med. 2007; 356: 2271-2281
        • Motzer R.J.
        • Escudier B.
        • Oudard S.
        • et al.
        Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors.
        Cancer. 2010; 116: 4256-4265
        • Hutson T.E.
        • Escudier B.
        • Esteban E.
        • et al.
        Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2014; 32: 760-767
        • Motzer R.J.
        • Jonasch E.
        • Agarwal N.
        • et al.
        Kidney cancer, version 3.2015.
        J Natl Compr Canc Netw. 2015; 13: 151-159
        • Hutson T.E.
        • Lesovoy V.
        • Al-Shukri S.
        • et al.
        Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
        Lancet Oncol. 2013; 14: 1287-1294
        • Rini B.I.
        • Melichar B.
        • Ueda T.
        • et al.
        Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
        Lancet Oncol. 2013; 14: 1233-1242
        • Rini B.I.
        • Escudier B.
        • Tomczak P.
        • et al.
        Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
        Lancet. 2011; 378: 1931-1939
        • Escudier B.
        • Roigas J.
        • Gillessen S.
        • et al.
        Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 4068-4075
        • Barrios C.H.
        • Hernandez-Barajas D.
        • Brown M.P.
        • et al.
        Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
        Cancer. 2012; 118: 1252-1259
        • Rini B.I.
        • Bellmunt J.
        • Clancy J.
        • et al.
        Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
        J Clin Oncol. 2014; 32: 752-759
        • Motzer R.J.
        • Hutson T.E.
        • Olsen M.R.
        • et al.
        Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
        J Clin Oncol. 2012; 30: 1371-1377
        • Motzer R.J.
        • Rini B.I.
        • Bukowski R.M.
        • et al.
        Sunitinib in patients with metastatic renal cell carcinoma.
        JAMA. 2006; 295: 2516-2524
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Tannir N.M.
        • Plimack E.
        • Ng C.
        • et al.
        A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
        Eur Urol. 2012; 62: 1013-1019
        • Lee J.L.
        • Ahn J.H.
        • Lim H.Y.
        • et al.
        Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.
        Ann Oncol. 2012; 23: 2108-2114
        • Koh Y.
        • Lim H.Y.
        • Ahn J.H.
        • et al.
        Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.
        Ann Oncol. 2013; 24: 1026-1031
        • Molina A.M.
        • Feldman D.R.
        • Ginsberg M.S.
        • et al.
        Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
        Invest New Drugs. 2012; 30: 335-340
        • Ravaud A.
        • Oudard S.
        • De Fromont M.
        • et al.
        First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG).
        Ann Oncol. 2015; 26: 1123-1128
        • Tannir N.M.
        • Jonasch E.
        • Albiges L.
        • et al.
        Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial.
        Eur Urol. 2016; 69: 866-874
        • Armstrong A.J.
        • Halabi S.
        • Eisen T.
        • et al.
        Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
        Lancet Oncol. 2016; 17: 378-388
        • Vera-Badillo F.E.
        • Templeton A.J.
        • Duran I.
        • et al.
        Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.
        Eur Urol. 2015; 67: 740-749
        • Creighton C.J.
        • Morgan M.
        • Gunaratne P.H.
        • et al.
        Comprehensive molecular characterization of clear cell renal cell carcinoma.
        Nature. 2013; 499: 43-49
        • Linehan W.M.
        • Spellman P.T.
        • et al.
        • Cancer Genome Atlas Research Network
        Comprehensive molecular characterization of papillary renal-cell carcinoma.
        N Engl J Med. 2016; 374: 135-145
        • Davis C.F.
        • Ricketts C.J.
        • Wang M.
        • et al.
        The somatic genomic landscape of chromophobe renal cell carcinoma.
        Cancer Cell. 2014; 26: 319-330
        • Choueiri T.K.
        • Vaishampayan U.
        • Rosenberg J.E.
        • et al.
        Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
        J Clin Oncol. 2013; 31: 181-186
        • Chen F.
        • Zhang Y.
        • Şenbabaoğlu Y.
        • et al.
        Multilevel genomics-based taxonomy of renal cell carcinoma.
        Cell Rep [Internet]. 2016; (Available at:) (Accessed: March 7, 2016)
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Beuselinck B.
        • Job S.
        • Becht E.
        • et al.
        Molecular subtypes of clear cell renal cell carcinoma are associated to sunitinib response in the metastatic setting.
        Clin Cancer Res. 2015; 21: 1329-1339
        • McDermott D.F.
        • Sosman J.A.
        • Sznol M.
        • et al.
        Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study.
        J Clin Oncol. 2016; 34: 833-842
        • Cangiano T.
        • Liao J.
        • Naitoh J.
        • Dorey F.
        • Figlin R.
        • Belldegrun A.
        Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
        J Clin Oncol. 1999; 17: 523-528
        • Cheville J.C.
        • Lohse C.M.
        • Zincke H.
        • et al.
        Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
        Am J Surg Pathol. 2004; 28: 435-441
        • Michaelson M.D.
        • McKay R.R.
        • Werner L.
        • et al.
        Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
        Cancer. 2015; 121: 3435-3443
        • Jonasch E.
        • Lal L.S.
        • Atkinson B.J.
        • et al.
        Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
        BJU Int. 2011; 107: 741-747
        • Bi M.
        • Zhao S.
        • Said J.W.
        • et al.
        Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
        Proc Natl Acad Sci U S A. 2016; 113: 2170-2175
        • Malouf G.G.
        • Ali S.M.
        • Wang K.
        • et al.
        Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations.
        Eur Urol. 2016; 70: 348-357
        • Choueiri T.K.
        • Escudier B.
        • Powles T.
        • et al.
        Cabozantinib versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1814-1823